Impact of the Immunonutritional Status on the Feasibility of Subsequent Treatment After the Discontinuation of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients With Metastatic Colorectal Cancer
A poor immunonutritional status at the initiation of FTD/TPI + Bev therapy may lead to a lower rate of transitioning to subsequent treatments, thus resulting in a worse prognosis.
Authors
- Yuki Seki (ORCID: https://orcid.org/0000-0002-3906-3506)
- Tomoya Tsukida
- Shinichiro Kashiwagi (ORCID: https://orcid.org/0000-0002-0460-9599)
- KIYOSHI MAEDA
- HIDEKI TANDA
- HIROAKI KASASHIMA
Institutions
- Osaka Metropolitan University (JP)
- The University of Osaka (JP)
Publication Details
- Journal
- Anticancer Research
- Published
- 2026-01-30
- DOI
- https://doi.org/10.21873/anticanres.18014
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00